Blocking TNF signaling may save lives in COVID-19 infection

Mol Biol Rep. 2022 Mar;49(3):2303-2309. doi: 10.1007/s11033-022-07166-x. Epub 2022 Jan 25.

Abstract

Global vaccination effort and better understanding of treatment strategies provided a ray of hope for improvement in COVID-19 pandemic, however, in many countries, the disease continues to collect its death toll. The major pathogenic mechanism behind severe cases associated with high mortality is the burst of pro-inflammatory cytokines TNF, IL-6, IFNγ and others, resulting in multiple organ failure. Although the exact contribution of each cytokine is not clear, we provide an evidence that the central mediator of cytokine storm and its devastating consequences may be TNF. This cytokine is known to be involved in activated blood clotting, lung damage, insulin resistance, heart failure, and other conditions. A number of currently available pharmaceutical agents such as monoclonal antibodies and soluble TNF receptors can effectively prevent TNF from binding to its receptor(s). Other drugs are known to block NFkB, the major signal transducer molecule used in TNF signaling, or to block kinases involved in downstream activation cascades. Some of these medicines have already been selected for clinical trials, but more work is needed. A simple, rapid, and inexpensive method of directly monitoring TNF levels may be a valuable tool for a timely selection of COVID-19 patients for anti-TNF therapy.

Keywords: Covid-19; Cytokine storm; Immune therapy; NFkappaB; Tumor Necrosis Factor (TNF).

Publication types

  • Review

MeSH terms

  • Biomarkers
  • COVID-19 / complications
  • COVID-19 / metabolism
  • COVID-19 Drug Treatment*
  • Cytokine Release Syndrome / drug therapy*
  • Cytokine Release Syndrome / etiology
  • Cytokine Release Syndrome / prevention & control
  • Drug Repositioning
  • Humans
  • Interleukin-6 / metabolism
  • Multiple Organ Failure / etiology
  • Multiple Organ Failure / prevention & control
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / metabolism
  • Pandemics*
  • Patient Selection
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • SARS-CoV-2*
  • Signal Transduction / drug effects
  • Tumor Necrosis Factor Inhibitors / pharmacology
  • Tumor Necrosis Factor Inhibitors / therapeutic use*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / physiology

Substances

  • Biomarkers
  • IL6 protein, human
  • Interleukin-6
  • NF-kappa B
  • Protein Kinase Inhibitors
  • Tumor Necrosis Factor Inhibitors
  • Tumor Necrosis Factor-alpha